BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 23106928)

  • 1. Neonatal neurobehavior effects following buprenorphine versus methadone exposure.
    Coyle MG; Salisbury AL; Lester BM; Jones HE; Lin H; Graf-Rohrmeister K; Fischer G
    Addiction; 2012 Nov; 107 Suppl 1(0 1):63-73. PubMed ID: 23106928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.
    Gaalema DE; Scott TL; Heil SH; Coyle MG; Kaltenbach K; Badger GJ; Arria AM; Stine SM; Martin PR; Jones HE
    Addiction; 2012 Nov; 107 Suppl 1(0 1):53-62. PubMed ID: 23106927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.
    Kaltenbach K; Holbrook AM; Coyle MG; Heil SH; Salisbury AL; Stine SM; Martin PR; Jones HE
    Addiction; 2012 Nov; 107 Suppl 1(0 1):45-52. PubMed ID: 23106926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal abstinence syndrome after methadone or buprenorphine exposure.
    Jones HE; Kaltenbach K; Heil SH; Stine SM; Coyle MG; Arria AM; O'Grady KE; Selby P; Martin PR; Fischer G
    N Engl J Med; 2010 Dec; 363(24):2320-31. PubMed ID: 21142534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.
    Metz V; Jagsch R; Ebner N; Würzl J; Pribasnig A; Aschauer C; Fischer G
    Hum Psychopharmacol; 2011 Aug; 26(6):412-21. PubMed ID: 21823171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months.
    Wouldes TA; Woodward LJ
    PLoS One; 2020; 15(10):e0240905. PubMed ID: 33064777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
    Sujan A; Cleary E; Douglas E; Aujla R; Boyars L; Smith C; Guille C
    Fam Pract; 2022 Mar; 39(2):311-315. PubMed ID: 34537839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
    Unger A; Jagsch R; Jones H; Arria A; Leitich H; Rohrmeister K; Aschauer C; Winklbaur B; Bäwert A; Fischer G
    Addiction; 2011 Jul; 106(7):1355-62. PubMed ID: 21438938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance.
    Klaman SL; Isaacs K; Leopold A; Perpich J; Hayashi S; Vender J; Campopiano M; Jones HE
    J Addict Med; 2017; 11(3):178-190. PubMed ID: 28406856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome.
    Tolia VN; Murthy K; Bennett MM; Miller ES; Benjamin DK; Smith PB; Clark RH
    J Perinatol; 2018 Jan; 38(1):75-79. PubMed ID: 29048415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
    Winhusen T; Wilder C; Wexelblatt SL; Theobald J; Hall ES; Lewis D; Van Hook J; Marcotte M
    Contemp Clin Trials; 2014 Sep; 39(1):158-65. PubMed ID: 25183042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Maternal Buprenorphine Dose Affect Severity or Incidence of Neonatal Abstinence Syndrome?
    Wong J; Saver B; Scanlan JM; Gianutsos LP; Bhakta Y; Walsh J; Plawman A; Sapienza D; Rudolf V
    J Addict Med; 2018; 12(6):435-441. PubMed ID: 29905586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.
    Jones HE; Johnson RE; Jasinski DR; O'Grady KE; Chisholm CA; Choo RE; Crocetti M; Dudas R; Harrow C; Huestis MA; Jansson LM; Lantz M; Lester BM; Milio L
    Drug Alcohol Depend; 2005 Jul; 79(1):1-10. PubMed ID: 15943939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.
    Pritham UA; Paul JA; Hayes MJ
    J Obstet Gynecol Neonatal Nurs; 2012 Mar; 41(2):180-190. PubMed ID: 22375882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital morphine preparation for abstinence syndrome in newborns exposed to buprenorphine or methadone.
    Colombini N; Elias R; Busuttil M; Dubuc M; Einaudi MA; Bues-Charbit M
    Pharm World Sci; 2008 Jun; 30(3):227-34. PubMed ID: 18008179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
    Jones HE; Heil SH; Baewert A; Arria AM; Kaltenbach K; Martin PR; Coyle MG; Selby P; Stine SM; Fischer G
    Addiction; 2012 Nov; 107 Suppl 1(0 1):5-27. PubMed ID: 23106923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal Abstinence Syndrome Severity Index Predicts 18-Month Neurodevelopmental Outcome in Neonates Randomized to Morphine or Methadone.
    Flannery T; Davis JM; Czynski AJ; Dansereau LM; Oliveira EL; Camardo SA; Lester BM
    J Pediatr; 2020 Dec; 227():101-107.e1. PubMed ID: 32805259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
    Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance agonist treatments for opiate-dependent pregnant women.
    Minozzi S; Amato L; Bellisario C; Ferri M; Davoli M
    Cochrane Database Syst Rev; 2013 Dec; (12):CD006318. PubMed ID: 24366859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.